Atazanavir

179 interactions 13 explained in plain English
Also sold as: Reyataz
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Irinotecan Lipid Complex Injection Midazolam Nasal Spray Encorafenib Lovastatin Lurasidone Colchicine
18 Contraindicated 134 Major 27 Moderate
All (179) Contraindicated (18) Major (134) Moderate (27)

Major

Atazanavir Lumateperone Caplyta Increased lumateperone exposure and increased risk of lumateperone-related adverse reactions Details Atazanavir Lurbinectedin Injection Zepzelca Increased lurbinectedin exposure and an increased risk of lurbinectedin-related adverse reactions Details Atazanavir Mefloquine Lariam® An increased risk of QT interval prolongation Details Atazanavir Metronidazole Flagyl An increased risk of QT interval prolongation Details Atazanavir Metronidazole Injection Flagyl An increased risk of QT interval prolongation Details Atazanavir Metronidazole Topical MetroCream® An increased risk of QT interval prolongation Details Atazanavir Metronidazole Vaginal MetroGel® Vaginal An increased risk of QT interval prolongation Details Atazanavir Mexiletine Mexitil® Increased antiarrhythmics exposure Details Atazanavir Minocycline Amzeeq Decreased atazanavir exposure and plasma concentrations Details Atazanavir Minocycline Topical Amzeeq Decreased atazanavir exposure and plasma concentrations Details Atazanavir Mitapivat Aqvesme Increased mitapivat exposure and reduced CYP3A4 substrate exposure Details Atazanavir Mometasone Asmanex Increased mometasone exposure and an increased risk of mometasone-related adverse reactions Details Atazanavir Mometasone Nasal Spray Nasonex Increased mometasone exposure and an increased risk of mometasone-related adverse reactions Details Atazanavir Mometasone Oral Inhalation Asmanex Increased mometasone exposure and an increased risk of mometasone-related adverse reactions Details Atazanavir Mometasone Topical Elocon® Increased mometasone exposure and an increased risk of mometasone-related adverse reactions Details Atazanavir Moxifloxacin Avelox Increased risk of QT interval prolongation Details Atazanavir Moxifloxacin Injection Avelox Increased risk of QT interval prolongation Details Atazanavir Moxifloxacin Ophthalmic Moxeza® Increased risk of QT interval prolongation Details Atazanavir Naloxegol Movantik Increased naloxegol exposure Details Atazanavir Nicardipine Cardene An increased risk of cardiotoxicity (prolonged PR interval) Details Atazanavir Nifedipine Adalat® Increased NIFEdipine exposure Details Atazanavir Nisoldipine Sular An increased calcium channel blocker exposure Details Atazanavir Nizatidine Axid® Reduced atazanavir exposure Details Atazanavir Octreotide Bynfezia An increased risk of QT interval prolongation Details Atazanavir Octreotide Injection Bynfezia An increased risk of QT interval prolongation Details Atazanavir Ofloxacin Floxin® An increased risk of QT interval prolongation Details Atazanavir Ofloxacin Ophthalmic Ocuflox An increased risk of QT interval prolongation Details Atazanavir Ofloxacin Otic Floxin® Otic An increased risk of QT interval prolongation Details Atazanavir Olaparib Lynparza Increased olaparib exposure Details Atazanavir Olodaterol Oral Inhalation Striverdi An increased risk of QT interval prolongation and an increased risk of ventricular arrhythmias Details Atazanavir Oxaliplatin Injection Eloxatin® Increased risk of QT-interval prolongation Details Atazanavir Orlistat Alli Reduced efficacy of antiretrovirals, loss of virological control Details

Moderate

Atazanavir Trospium / Xanomeline Cobenfy Explained Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Atazanavir Abemaciclib Verzenio Explained Increased abemaciclib plasma concentration Details Atazanavir Acebutolol Sectral® An increased risk of PR interval prolongation Details Atazanavir Betaxolol Betoptic S An increased risk of PR interval prolongation Details Atazanavir Betaxolol Ophthalmic Betoptic® An increased risk of PR interval prolongation Details Atazanavir Canagliflozin Invokana Worsening glycemic control Details Atazanavir Cyclosporine Injection Atopica Increased cycloSPORINE exposure Details Atazanavir Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.